

Health Care: Drugs
SciClone Pharmaceuticals (SCLN: NASDAQ)
$4.86 -0.11 | -2.21%
05/24/13 - 04:00 PM ET
Portfolios with SCLN
Latest SCLN Headlines from TheStreet
More Financial News for SCLN
Press Releases for SCLN
- Kahn Swick & Foti, LLC Announce Continuing Investigation Into SciClone Pharmaceuticals, Inc. – Firm Appointed Co-lead Counsel In Securities Class Action – SCLN - Business Wire 11.02.10 | 06:11 pm
- Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against SciClone Pharmaceuticals, Inc. - Business Wire 09.23.10 | 10:09 am
- Ryan & Maniskas, LLP Announces Class Action Lawsuit Against SciClone Pharmaceuticals, Inc. - Business Wire 08.20.10 | 07:08 pm
- Kendall Law Group Investigates SciClone Pharmaceuticals, Inc. For Shareholders - Business Wire 08.20.10 | 01:08 pm
- Robbins Umeda LLP Announces Investigation Of SciClone Pharmaceuticals, Inc. - Business Wire 08.12.10 | 07:08 pm
- Finkelstein Thompson LLP Announces Investigation Of SciClone Pharmaceuticals, Inc. - Business Wire 08.11.10 | 04:08 pm
- Goldfarb Branham LLP Investigating SciClone Pharmaceuticals For Investors - Business Wire 08.11.10 | 12:08 pm
- Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Shareholders Of SciClone Pharmaceuticals, Inc. - Business Wire 08.10.10 | 08:08 pm
- Levi & Korsinsky, LLP Investigates SciClone Pharmaceuticals, Inc. - Business Wire 08.10.10 | 08:08 pm
- Roy Jacobs & Associates Investigating SciClone Pharmaceuticals, Inc. For Possible Securities Law Violations ("SCLN") - Business Wire 08.10.10 | 05:08 pm
See All Press Releases
Partner Headlines for SCLN